Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lavelle

Showing results (1-10 of 174) with videos related to

Pageof 18
Sort By:
Pathologie-Biologie|January 1, 1987
[Structure and activity of anthracyclines]F Lavelle
Bulletin Du Cancer|February 24, 2001
[How to make an ally of an "inactive" product: the example of interferon]F Lavelle
Expert Opinion on Investigational Drugs|June 1, 1997
American Association for Cancer Research 1997: progress and new hope in the fight against cancerF Lavelle
Expert Opinion on Investigational Drugs|July 5, 2005
American Association for Cancer Research 1999: 10-14 April, Philadelphia, PennsylvaniaF Lavelle
Bulletin Du Cancer|February 25, 1999
[New anticancer molecules: drugs for tomorrow?]F Lavelle
Bulletin Du Cancer|February 15, 2001
[11th symposium on new antineoplastic drugs (Amsterdam, November 7-10, 2000): small series or great hopes?]F Lavelle
Bulletin Du Cancer|March 8, 2000
[MIF and P53: 2 major partners at the inflammation and cancer crossroad]F Lavelle
Bulletin Du Cancer|December 4, 1998
[Preclinical evaluation of anticancer drugs: a model remaining a model!]F Lavelle
Bulletin Du Cancer|December 28, 1999
[Telomerases: transformation trial!]F Lavelle
Bulletin Du Cancer|July 1, 1997
[Tyrosine protein kinase inhibitors in cancerology: the end of the beginning?]F Lavelle
Pageof 18

Showing results (1-10 of 174) with videos related to

Sort By:
Pageof 18
Pathologie-Biologie|January 1, 1987
[Structure and activity of anthracyclines]F Lavelle
Bulletin Du Cancer|February 24, 2001
[How to make an ally of an "inactive" product: the example of interferon]F Lavelle
Expert Opinion on Investigational Drugs|June 1, 1997
American Association for Cancer Research 1997: progress and new hope in the fight against cancerF Lavelle
Expert Opinion on Investigational Drugs|July 5, 2005
American Association for Cancer Research 1999: 10-14 April, Philadelphia, PennsylvaniaF Lavelle
Bulletin Du Cancer|February 25, 1999
[New anticancer molecules: drugs for tomorrow?]F Lavelle
Bulletin Du Cancer|February 15, 2001
[11th symposium on new antineoplastic drugs (Amsterdam, November 7-10, 2000): small series or great hopes?]F Lavelle
Bulletin Du Cancer|March 8, 2000
[MIF and P53: 2 major partners at the inflammation and cancer crossroad]F Lavelle
Bulletin Du Cancer|December 4, 1998
[Preclinical evaluation of anticancer drugs: a model remaining a model!]F Lavelle
Bulletin Du Cancer|December 28, 1999
[Telomerases: transformation trial!]F Lavelle
Bulletin Du Cancer|July 1, 1997
[Tyrosine protein kinase inhibitors in cancerology: the end of the beginning?]F Lavelle
Pageof 18